These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 34270172)
1. The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018. Bardsley M; Heinsbroek E; Harris R; Croxford S; Edmundson C; Hope V; Hassan N; Ijaz S; Mandal S; Shute J; Hutchinson SJ; Hickman M; Sinka K; Phipps E J Viral Hepat; 2021 Oct; 28(10):1452-1463. PubMed ID: 34270172 [TBL] [Abstract][Full Text] [Related]
2. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446 [TBL] [Abstract][Full Text] [Related]
3. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897 [TBL] [Abstract][Full Text] [Related]
4. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J; Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635 [TBL] [Abstract][Full Text] [Related]
5. Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland: A quantitative cross-sectional analysis. Yuan JM; Croxford S; Viviani L; Emanuel E; Phipps E; Desai M Int J Drug Policy; 2022 Nov; 109():103821. PubMed ID: 35994940 [TBL] [Abstract][Full Text] [Related]
6. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy. Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585 [TBL] [Abstract][Full Text] [Related]
7. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington. Corcorran MA; Tsui JI; Scott JD; Dombrowski JC; Glick SN Drug Alcohol Depend; 2021 Mar; 220():108525. PubMed ID: 33461152 [TBL] [Abstract][Full Text] [Related]
8. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387 [TBL] [Abstract][Full Text] [Related]
9. Geographic variation in HCV treatment penetration among people who inject drugs in Baltimore, MD. Coyle CR; Desjardins MR; Curriero FC; Rudolph J; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH; Genberg BL J Viral Hepat; 2023 Oct; 30(10):810-818. PubMed ID: 37382024 [TBL] [Abstract][Full Text] [Related]
10. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era. Falade-Nwulia O; Gicquelais RE; Astemborski J; McCormick SD; Kirk G; Sulkowski M; Thomas DL; Mehta SH Liver Int; 2020 Oct; 40(10):2407-2416. PubMed ID: 32770638 [TBL] [Abstract][Full Text] [Related]
11. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050 [TBL] [Abstract][Full Text] [Related]
12. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194 [TBL] [Abstract][Full Text] [Related]
13. Improved health-related quality of life after hepatitis C viraemic clearance among people who inject drugs may not be durable. McDonald SA; Myring G; Palmateer NE; McAuley A; Beer L; Dillon JF; Hollingworth W; Gunson R; Hickman M; Hutchinson SJ Addiction; 2023 Jul; 118(7):1340-1350. PubMed ID: 36808787 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study. Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914 [TBL] [Abstract][Full Text] [Related]
15. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies. Iversen J; Wand H; McManus H; Dore GJ; Maher L Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842 [TBL] [Abstract][Full Text] [Related]
16. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB; Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989 [TBL] [Abstract][Full Text] [Related]
17. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019. Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K; Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902 [TBL] [Abstract][Full Text] [Related]
18. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals. Coyle CR; Gicquelais RE; Genberg BL; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH Drug Alcohol Depend; 2023 Dec; 253():. PubMed ID: 38456165 [TBL] [Abstract][Full Text] [Related]
19. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). Hickman M; Dillon JF; Elliott L; De Angelis D; Vickerman P; Foster G; Donnan P; Eriksen A; Flowers P; Goldberg D; Hollingworth W; Ijaz S; Liddell D; Mandal S; Martin N; Beer LJZ; Drysdale K; Fraser H; Glass R; Graham L; Gunson RN; Hamilton E; Harris H; Harris M; Harris R; Heinsbroek E; Hope V; Horwood J; Inglis SK; Innes H; Lane A; Meadows J; McAuley A; Metcalfe C; Migchelsen S; Murray A; Myring G; Palmateer NE; Presanis A; Radley A; Ramsay M; Samartsidis P; Simmons R; Sinka K; Vojt G; Ward Z; Whiteley D; Yeung A; Hutchinson SJ BMJ Open; 2019 Sep; 9(9):e029538. PubMed ID: 31551376 [TBL] [Abstract][Full Text] [Related]
20. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]